Showing results (411-420 of 454) with videos related to

Sort By:
Pageof 46
Eclinicalmedicine|April 30, 2024
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trialsEva Blondeaux, Wanling Xie, Luca Carmisciano, et al.
Cancers|December 30, 2025
Pregnancy vs. Postpartum Breast Cancer: Distinct Tumor Biology and Survival Trends in a Contemporary CohortElena Jane Mason, Alba Di Leone, Beatrice Carnassale, et al.
The Lancet. Oncology|September 20, 2021
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trialLucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, et al.
Oncotarget|October 4, 2017
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter studyAlessandra Fabi, Michelino De Laurentiis, Michele Caruso, et al.
Breast (Edinburgh, Scotland)|May 29, 2026
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER studyLetizia Pontolillo, Elisabetta Munzone, Paolo Vigneri, et al.
The Oncologist|November 23, 2023
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL StudyAndrea Botticelli, Roberta Caputo, Simone Scagnoli, et al.
The Lancet. Oncology|December 8, 2018
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trialGiuseppe Lombardi, Gian Luca De Salvo, Alba Ariela Brandes, et al.
Life (Basel, Switzerland)|April 26, 2025
Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes TumorsFlavia De Lauretis, Alejandro Martin Sanchez, Cristina Accetta, et al.
The Lancet. Oncology|November 12, 2022
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, Francesca Poggio, Eva Blondeaux, et al.
Cancers|October 14, 2023
Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE StudyStefania Gori, Alessandra Fabi, Catia Angiolini, et al.
Pageof 46